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Abstract
Background: Oral administration of BCG was the route initially used by Calmette and Guérin,
but was replaced by intradermal administration in virtually all countries after the Lubeck accident.
However, Brazil continued to administer oral BCG Moreau RDJ, which was maintained until the
mid-1970s when it was substituted by the intradermal route. Although BCG vaccination has been
used in humans since 1921, little is known of the induced immune response. The aim of this study
was to analyse immunological responses after oral vaccination with M. bovis BCG Moreau RDJ.
Methods: This study in healthy volunteers has measured cellular and humoral aspects of the
immunological response to oral M. bovis BCG Moreau RDJ in Rio de Janeiro, Brazil. T-cell trafficking
and Th1 and Th2 cytokine responses are described, as well as isotype-specific antibody production
using novel techniques.
Results: Oral immunisation has no adverse effects. We have shown that there are cellular and
humoral immunological responses after oral immunisation. Oral revaccination does not induce a
positive skin test in responsive individuals and multiple booster orally was able to induce
modulation in humoral immunological responses (switch from IgG to IgA) in previously immunised
subjects and incapable of inducing tolerance. In contrast, the cellular immune response does not
differ between vaccinated individuals with positive and negative skin test reactions.
Conclusion:  All subjects, including those who did not respond to the skin test at study
commencement, were capable of mounting humoral and cellular immune response to the antigens
tested.
Background
BCG vaccination was developed by attenuation in vitro
over 13 years from a virulent sample of Mycobacterium
bovis by Albert Calmette and Camille Guérin at the Pasteur
Institute, Lille. The attenuated strain named BCG (Bacillus
of Calmette-Guérin) is now known as Mycobacterium bovis
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BCG. BCG was given to humans for the first time in 1921,
since when it has become the most used vaccine in the
world [6]. It has been given to 3 billion people with low
incidence of serious adverse events [18]; more than 100
million people currently receive the vaccine in order to
prevent tuberculosis [23]. More than 90% of global pro-
duction is made of the Russian BCG-I, Tokyo 172-1, Dan-
ish 1331, Moreau RDJ and Pasteur 1173-P2 sub strains
[19].
Despite use of the vaccine for more than 80 years, several
controversies remain concerning efficacy, with studies
reporting protection rates varying between 0 and 80%
[12,13,4,11].
Oral administration was the route initially used by Cal-
mette and Guérin, but was replaced by intradermal
administration in virtually all countries after the Lubeck
accident, in which 67 of 249 babies given the vaccine died
due to contamination of the BCG with virulent Mycobacte-
rium tuberculosis [2]. However, Arlindo de Assis continued
to administer oral BCG, which was maintained in Brazil
until the mid-1970s when it was substituted by the intra-
dermal route. Even after this change in route, the
Fundação Ataulpho de Paiva continued to produce the
oral vaccine [7].
Studies by Assis and Carvalho [3] showed that none of
167 children developed a response to skin testing one
week after oral immunisation; skin-test positivity only
appeared from 6 weeks after oral immunisation with BCG
Moreau.
It is known that induction of the mucosal immune
response is vital for protection against infectious agents
whose route of entry is via the mucosa, as is the case for
tuberculosis. Oral administration was shown capable of
inducing a more substantial mucosal and systemic
immune response compared to the intradermal route
[16].
Brown et al (2003) [9] showed that BCG could induce
mycobacteria-specific antibodies and Williams et al
(2004) [26] confirmed that oral vaccination with BCG
induced significant increases in IgA isotype anti-LAM anti-
bodies that had important functions in systemic
responses as well as offering mucosal protection.
Host resistance to mycobacterial invasion is associated
principally with generation of cellular immune responses
[15].
CD4+ T cells become activated after presentation of myco-
bacterial antigens in association with class II MHC mole-
cules, producing cytokines, principally IFN-γ, the
principal activator of macrophages [25] that acts in con-
junction with TNF-α to recruit macrophages, augmenting
the effectiveness of host immune responses [22].
CD8+ T cells are also capable of secreting cytokines includ-
ing IFN-γ, TNF-α, IL-2 and IL-4 and are important in con-
trolling the equilibrium between Th1 and Th2 responses
[25]. Deficiency of these cells provokes poorly organised
cellular infiltrates suggesting their importance in the for-
mation of protective granulomas [1]. In addition, these
cells appear to have an important role in protection
against reactivation of latent infection [21].
Once mycobacteria become intracellular pathogens,
serum components cannot gain access and lose their pro-
tective function [25]. B-cells have been described as an
important source of chemokines involved in granuloma
development and consequently inhibit mycobacterial dis-
semination, resulting in recruitment of appropriate cells
to the locality for the first few weeks after infection [8].
The concept of a common mucosal-associated system reg-
ulating and coordinating immune responses at mucosal
surfaces has been an important advance in our under-
standing of protection against mucosal pathogens. This
system is based on primed T and B lymphocytes that
migrate from the site of antigen presentation via lymphat-
ics and blood to selectively "home" to lymphoid tissue at
distant sites in gastrointestinal, respiratory, genitourinary
and other mucosa-associated regions [17].
In this context, the objective of this study was to analyse
humoral and cellular immune responses to mycobacterial
antigens and correlate them to the PPD skin tests in
healthy adult volunteers in Rio de Janeiro (Brazil) after
oral vaccination with M. bovis BCG Moreau RDJ.
Methods
Volunteers and skin testing
Healthy subjects aged 18–50 years were recruited who
gave no history of pulmonary illness, tuberculosis or
Hansen's disease, and in whom clinical examination and
chest X-ray were within normal limits. For PPD skin test-
ing, Multi-test (Mérieux®) was applied to the right arm and
read after 48 hours. Volunteers were retested for skin reac-
tivity at the end of the study (6 months after oral immu-
nisation). Written informed consent was obtained from
participants before study enrollment.
Antigens
Antigens used were M. bovis BCG vaccine Moreau RDJ,
secreted proteins from M. bovis BCG Moreau RDJ culture
and PPD Rt48 (Statens Serum Institute).Journal of Immune Based Therapies and Vaccines 2006, 4:4 http://www.jibtherapies.com/content/4/1/4
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Vaccination
Over a 90 minute period of fasting subjects received 100
ml 2% sodium bicarbonate to neutralise gastric acid and
after a gap of 15 minutes were orally immunised with 5 ml
M. bovis BCG Moreau RDJ vaccine at a concentration of 20
mg/ml (made by Fundação Ataulpho de Paiva).
Blood collection and collection of peripheral blood 
mononuclear cells (PBMC)
Blood samples were taken before immunisation (counted
on a negative scale), on the day of immunisation (day
zero) and on days 3, 5, 7, 10, 12, 14 and 19 after oral
immunisation with M. bovis BCG Moreau RDJ. PBMC were
separated from heparinised blood by a density gradient
and lymphocytes were washed and counted prior to use in
experiments.
ELISpot
Between 5 × 105 and 1 × 106 PBMC were transferred to 25-
well plates pre-coated with 20 μg/ml oral M. bovis BCG
Moreau RDJ vaccine and incubated for 2 1/2 hours at
37°C in 5% CO2. Anti-IgA (2 μg/ml), anti-IgG (2 μg/ml)
and anti-IgM (4 μg/ml) anti-human antibodies were
added and incubated for 2 hours. Goat anti-human anti-
body conjugated with alkaline phosphatase (2 μg/ml) was
incubated for 2 hours prior to development using BCIP.
Wells were read under an inverted microscope after 3
hours of development.
Cellular lymphoproliferation
U-shaped 96-well plates were coated with secreted BCG
proteins or PPD Rt48 (both 10 μg/ml); mitogen used was
concanavalin A (2.5 μg/ml). Mean 3H incorporation
(cpm) was measured in triplicate by scintillation counting
in a Beta counter for 1 minute.
Cytokine measurement
Supernatants of cellular lymphoproliferation assays were
frozen at -70°C for subsequent measurement of cytokines
IL-4 and IFN-γ using highly sensitive kits RPN-2783 and
RPN-2787 (Amersham®  LIFE SCIENCE) respectively
according to manufacturer's instructions.
Results
Skin test responses and correlation with vaccine history
Of 100 individuals assessed for PPD skin reactivity, 77
(77%) were positive and 23 (23%) negative (figure 1). Of
the 23 PPD negative individuals, 19 had been immunised
orally and 3 intradermally in infancy and 1 had not been
immunised (figure 2). Only 6 subjects consented to the
immune response kinetic study (Table 1) and just two of
them agreed to have an oral booster vaccination 42 days
after primary immunisation. Of these 6 subjects, 3 gave a
history of contact with tuberculosis (subjects 2, 5 and 6).
All subjects were tested for PPD 6 months after oral
immunisation and the results were similar to the first
tests. Subjects who responded positively to skin testing
were evaluated clinically and none showed symptoms or
signs of infection.
Humoral response (ELISpot)
Using the ELISpot technique it was possible to observe the
quantity and isotype of antibody production by plasmab-
lasts in response to oral immunisation with M. bovis BCG
Moreau RDJ. Results were expressed in terms of the
number of spots formed per 106 PBMC. Despite differences
in the number of spots, all subjects displayed a peak
humoral immune response, observed by the detection of
IgG antibodies, between day 10 and 14 after oral immu-
nisation (figure 1). Subjects 2 and 6, who received more
than one dose of oral vaccine and had been immunised in
ELISpot IgA and IgG – Volunteers 2 and 6 Figure 2
ELISpot IgA and IgG – Volunteers 2 and 6. Subjects 2 
and 6, who received more than one dose of oral vaccine and 
had been immunised in infancy via the oral and intradermal 
routes respectively, displayed an altered humoral immune 
response with antibodies of isotype IgA. Arrows indicate 
time of immunisation and booster.
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ELISpot IgG Figure 1
ELISpot IgG. Although differences in the number of spots, 
all subjects displayed a peak humoral immune response, 
observed by the detection of IgG. Arrow indicates time of 
immunisation and booster.
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infancy via the oral and intradermal routes respectively,
displayed an altered humoral immune response with anti-
bodies of isotype IgA; subject 2 displayed earlier and
greater expression on day 12 after immunisation and 12
days after boosting with oral vaccine (day 49) appeared a
new peak of IgA expression. Subject 6 (primary Id vaccina-
tion at birth) presented IgA immune response after oral
immunisation and kept expressive levels of IgG after oral
immunisation. In contrast volunteer 2 (primary oral vac-
cination at birth) kept the previous expression of IgA and
presented no IgG immune response (figure 2).
Cellular lymphoproliferation and cytokine response to 
PPD Rt 48
Cytokines were analysed for all subjects except subject 6
with the objective of observing Th1 (represented by IFN-γ)
and Th2 (represented by IL-4) responses.
All subjects showed a lymphoproliferative response to
PPD Rt48 although the magnitude of stimulation differed
(figures 3 and 4). Volunteers 1 to 5 showed production of
IFN-γ and 1 to 6 showed lymphoproliferative responses to
PPD Rt48. The peak production of IFN-γ was 30 pg/ml for
volunteer 1, 330 pg/ml for volunteer 2, 380 pg/ml for vol-
unteer 3, 40 pg/ml for volunteer 4 and 50 pg/ml for vol-
unteer 5. The stimulation indices (SI = cpm tested: cpm
control – RPMI medium) of the same subjects were
respectively: 45, 90, 20, 4, 50 and 8.
With regard to cytokine production in response to
secreted proteins, production of IFN-γ was observed,
peaking at day 7 after oral immunisation. Levels of expres-
sion differed between individuals, but kinetics were main-
tained. All subjects were capable of IL-4 production in
response to secreted proteins although no peak was
observed; instead constant production of this cytokine
was observed over the study period (data not shown).
Discussion
Use of intradermal BCG vaccination results in a greater
number of individuals capable of responding to skin test-
ing, but the durability of this response varies between
individuals and the diameter of induration diminishes
with time. In some programmes, negative skin test
response to PPD has been interpreted as an indication for
revaccination. According to Hoft et al (2000) [20], immu-
nisation with oral BCG inhibits DTH responses, but this
inhibition does not represent a state of tolerance, since
Cell lymphoproliferation to PPD Rt 48 Figure 4
Cell lymphoproliferation to PPD Rt 48. All subjects 
showed a lymphoproliferative response to PPD Rt48 
although the magnitude of stimulation differed. Arrows indi-
cate time of immunisation.
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Table 1: Clinical characteristics of the volunteers.
Volunteer Age Gender PPD result Chest X-Ray TB exposure First Immunisation
1 50 F - Normal NO Oral
2 40 M - Normal YES Oral
3 33 F - Normal NO Oral
4 23 F - Normal NO I.D.
5 25 F + Normal YES I.D.
6 35 F + Normal YES I.D.
IFN-γ production and PPD Rt 48 Figure 3
IFN-γ production and PPD Rt 48. Subjects displayed 
peak production of IFN-γ in response to PPD Rt 48 between 
days 5 and 12. Arrows indicate time of immunisation.
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these individuals show significant mycobacteria-specific
IFN-γ responses. Another hypothesis to explain the pau-
city or lack of DTH response in orally immunised individ-
uals is that different populations of T cells are activated by
BCG vaccination via the oral and intradermal routes [20].
We also observed that two individuals who received
boosting with oral BCG vaccine during the study showed
an alteration in humoral immune response seen as a shift
in isotype from IgG to IgA, suggesting that oral revaccina-
tion is capable of provoking cellular and humoral
responses. This response is independent of the route used
in previous vaccination. Given that tuberculosis affects an
important mucosal site, the respiratory tract, the potential
use of oral booster vaccination in immunisation pro-
grammes is of interest. Subjects who were not boosted
were not capable of mounting this shift in immunoglob-
ulin isotype for the antigens tested. Hoft et al (2000) [20]
propose a combination of oral and intradermal routes for
BCG vaccination with the objective of inducing protective
mucosal and systemic immunity against initial infection
and systemic progression.
The kinetics of lymphoproliferative response described in
this study are similar to those previously described using
oral cholera vaccine [10]. Like our previous study, we can
demonstrate that proliferation and trafficking of primed
T-cells shows stimulation of the mucosal immune
response at the same time as the systemic immune
response; peak responses in this study (d7-12) are similar
to those seen by Castello-Branco et al (1994) [10].
There were no differences in kinetics of T-cell circulation
between PPD skin test responders and non-responders.
All subjects developed a lymphoproliferative response
after immunisation, suggesting the existence of circulating
T-cells homing to the site where they were primed. Immu-
nisation with M. bovis BCG Moreau RDJ was capable of
altering the immune response to the cellular arm (Th1),
critical for protection against infection, without failing to
stimulate the humoral immune response (Th2) necessary
for control of the cellular response [24,1].
It is important to remember that half the subjects reported
contact with tuberculosis patients, and that contact with
atypical mycobacteria could have influenced ELISpot
results, an index of immune stimulation by mycobacterial
antigens. Age, which varied between 18 and 50 years,
could also have contributed to differences in responses.
A previous study (Das et al 1998) [14] of BCG vaccination
in PPD skin test negative individuals showed a lack of
IFN-γ response after immunisation. The strain of BCG
used in immunisation may influence immune responses.
As well as being is one of the most immunogenic BCG
strains, M. bovis BCG Moreau RDJ shows great similarity to
the original strain produced by Calmette and Guérin; only
the BCG Russia strain genetically closer to the original, but
is associated with a high incidence of adverse events
including BCG osteitis [6]. These genetic strain differences
are clearly of fundamental importance in determining
immune responses as well as virulence [5].
This study demonstrates, for the first time, the immune
response to oral immunisation with M. bovis BCG Moreau
RDJ in humans. All subjects, including those who did not
respond to the skin test at study commencement, were
capable of mounting humoral and cellular immune
responses to the antigens tested.
The data presented here will form the basis for further
studies with larger numbers of subjects, with the aim of
studying additional variables including immunoglobu-
lins isotypes, other cytokines of importance in mucosal
immune responses as well as responses to purified
secreted proteins.
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